Pharmaceuticals

Rising Gastrointestinal Disease Prevalence Fueling Growth Due To Increasing Demand For Targeted Treatment Is Supporting Expansion In The Osimertinib Drugs Market

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Osimertinib Drugs Market Between 2026 And 2030?

The osimertinib drugs market size has experienced rapid expansion in recent years. It is anticipated to increase from $7.75 billion in 2025 to $8.94 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.3%. The historical period’s growth can be attributed to several factors, including the rising incidence of NSCLC, increased EGFR mutation testing, clinical success surpassing first-generation TKIs, regulatory approvals granted in major markets, and growing expenditure within oncology healthcare.

The osimertinib drugs market is projected to experience substantial expansion over the coming years, set to reach $16.25 billion by 2030 with a compound annual growth rate (CAGR) of 16.1%. This growth during the forecast period is primarily attributable to the broadening of precision oncology initiatives, rising diagnosis rates in developing economies, the creation of next-generation egfr inhibitors, expanded reimbursement options, and ongoing clinical investigations for additional indications. Key trends anticipated within this period involve the increased application as a first-line egfr therapy, greater acceptance in treating metastatic nsclc, a heightened preference for oral targeted treatments, an uptick in combination therapy research, and enhanced patient adherence due to once-daily dosing.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13255&type=smp

Which Strong Drivers Are Impacting The Osimertinib Drugs Market Growth?

The rising occurrence of lung cancer is anticipated to fuel the expansion of the osimertinib drug market in the future. Lung cancer is defined as a form of cancer that begins in the lung tissues, primarily within the cells lining the airways. Osimertinib serves as a treatment option for lung cancer, working to inhibit the function of specific proteins crucial for the proliferation and dissemination of cancer cells. For example, data released in January 2023 by the American Cancer Society Facts and Figures, a US-based professional organizations company, indicated that new cases of lung and bronchus cancer were estimated at 236,740 in 2022 and 238,340 in 2023, with estimated deaths at 130,180 in 2022 and 127,070 in 2023. Consequently, the growing incidence of lung cancer is stimulating the growth of the osimertinib drug market. The expanding efforts by organizations to enhance lung cancer care and treatment are anticipated to advance the osimertinib drug market in the coming years. Such organizational initiatives for improving lung cancer care and treatment encompass policies, financial support, and various programs enacted by these entities to increase the availability, cost-effectiveness, and standard of care for patients with cancer. Organizations have introduced measures specifically aimed at improving lung cancer care, often by optimizing the application of the osimertinib drug to achieve more effective outcomes. A notable example is the implementation of the National Lung Cancer Screening Program (NLCSP) by The Australian Department of Health and Aged Care, an Australia-based government agency, in May 2024. This program seeks to establish a systematic method for the early detection of lung cancer through low-dose computed tomography (LDCT) scans, targeting high-risk individuals, especially those aged 50 to 80 with a substantial smoking background. Consequently, the growing number of initiatives from organizations to improve lung cancer care and treatment is propelling the growth of the osimertinib drug market.

How Is Segmentation Applied In The Osimertinib Drugs Market Segment Analysis?

The osimertinib drugs market covered in this report is segmented –

1) By Type: 40 mg, 80 mg

2) By Distribution Channel: Hospital Pharmacy, Drug Store And Retail Pharmacy, Online Pharmacy

3) By Application: Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Other Applications

Subsegments:

1) By 40 mg: Maintenance Therapy in Tolerability-Sensitive Patients, Dose Adjustment for Drug–Drug Interactions

2) By 80 mg: First-Line Treatment for EGFR-Mutated NSCLC, Second-Line Treatment for T790M-Positive NSCLC

Which Trends Are Shaping Growth In The Osimertinib Drugs Market?

Major companies operating in the osimertinib drugs market are prioritizing targeted therapies to achieve better outcomes for patients with non-small cell lung cancer (NSCLC), particularly those exhibiting EGFR mutations, aiming to elevate treatment efficacy and patient quality of life. These firms are additionally committing investments to clinical trials and research partnerships to expand osimertinib’s applications and assess its effectiveness in conjunction with other treatments for broader patient benefits. As an example, in September 2024, AstraZeneca Pharmaceuticals LP, a US-based pharmaceutical company, introduced osimertinib (Tagrisso) for adults with locally advanced, unresectable non-small cell lung cancer (NSCLC) featuring specific EGFR mutations, following FDA approval. This clearance was a result of a clinical trial that evidenced significant improvements in progression-free survival when contrasted with a placebo.

Who Are The Companies Participating In The Osimertinib Drugs Market Environment?

Major companies operating in the osimertinib drugs market are AstraZeneca plc, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Aristo Pharmaceuticals Private Limited, Incepta Pharmaceuticals Ltd., Beacon Pharmaceutical Limited, Drug International Limited, MSN Laboratories Pvt Ltd., Hetero Drugs Ltd., Accord Healthcare Limited, Dolphin Pharmaceutical Limited, Radiant Pharmaceuticals Ltd., Beximco Pharmaceuticals Ltd., Eskayef Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Natco Pharma Limited, Alkem Laboratories Ltd.

Get The Full Osimertinib Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/osimertinib-drugs-global-market-report

Where Is The Osimertinib Drugs Market Primarily Concentrated By Region?

North America was the largest region in the osimertinib drugs market in 2025. The regions covered in the osimertinib drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Osimertinib Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/osimertinib-drugs-global-market-report

Browse Through More Reports Similar to the Global Osimertinib Drugs Market 2026, By The Business Research Company

Osimertinib Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/osimertinib-drugs-global-market-report

Osteoporosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report

Alexipharmic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alexipharmic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795